Antibe Therapeutics (Antibe Therapeutics) ROE % Adjusted to Book Value : -32.71% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Antibe Therapeutics ROE % Adjusted to Book Value?

Antibe Therapeutics's ROE % for the quarter that ended in Dec. 2023 was -60.84%. Antibe Therapeutics's PB Ratio for the quarter that ended in Dec. 2023 was 1.86. Antibe Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -32.71%.

Antibe Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Antibe Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics ROE % Adjusted to Book Value Chart

Antibe Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-17.82

-7.42

-21.17

-63.03

-48.53

Antibe Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-71.68	-42.90	-89.60	-71.49	-32.71

Competitive Comparison of Antibe Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Antibe Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antibe Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's ROE % Adjusted to Book Value falls into.

Antibe Therapeutics ROE % Adjusted to Book Value Calculation

Antibe Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-38.34%	/	0.79
	=	-48.53%

Antibe Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-60.84%	/	1.86
	=	-32.71%

Antibe Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Antibe Therapeutics (Antibe Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (OTCPK:ATBPF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

ATE:Canada

Address

15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2

Website

https://www.antibethera.com

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.